Q3 Earnings Spotlight: Abiomed Shines Among Cardiology Device-Makers
Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.
You may also be interested in...
The list of medical device approvals outside the US captured by Medtech Insight's Approvals Tracker in 2018 was shorter than in 2017, but it includes approvals from 14 different territories – more than one-fifth of the approvals came from emerging markets – covering more than 50 different indication categories.
Promising new results from a pilot study of Abiomed’s Impella device to reduce damage after myocardial infarction sets the company up to start a pivotal study, which, if successful, could change how patients are treated immediately after an attack.
Devices that collect and communicate patient data present opportunities for device-makers to have a closer relationship with end-users, but most device companies have little experience working directly with patients. Device firms need to close this gap by seeing the patients who use their devices as their primary customers, rather than just focusing on intermediaries like doctors, hospitals, and payers, industry experts tell Medtech Insight.